23rd May 2016 06:58
LONDON (Alliance News) - Biotherapeutics developer 4d Pharma PLC on Monday said its irritable bowel syndrome treatment Blautix met its primary endpoint in its recently-completed phase 1 trial.
The trial showed Blautix to be safe and well-tolerated, meaning it met its primary endpoint, 4d Pharma said.
Data from the trials is being collected, and 4d said it will provide further information in this in coming weeks.
"This is a further step towards taking our pipeline, and live biotherapeutics as a class, to market approval. We have shown Blautix to be safe and well tolerated, which we have always believed would be a keystone to the field of live biotherapeutics," said 4d Chief Executive Duncan Peyton.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
DDDD.L